Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: John Romeo who wrote (5601)	10/27/1998 2:05:00 PM
From: Biomaven	Read Replies (2) \| Respond to of 6136

Short interest in AGPH dropped sharply, from 8.3 million shares last month to 6.7 million shares as of 10/26. Still a ways to go, though <G>. Interestingly, the CNTO short position also dropped 1.6 million shares. My instinct is that the emerging mid-cap biotechs like AGPH and CNTO play a key role in the overall biotech market. While there was easy money being made shorting these in volume, third-tier biotechs were unlikely to do well. Now that the shorts may be thinking twice, with biotechs showing good relative strength, I am somewhat more hopeful for the truly beaten down with good science (like Rick's T/FIF portfolios). Peter